logo
Plus   Neg
Share
Email

MTU Aero Engines Q4 Results Down; Lifts Dividend; Sees Higher FY21 Revenues - Quick Facts

German aircraft engine manufacturer MTU Aero Engines AG (MTUAY.PK) reported Thursday that its fourth-quarter net income plunged to 6 million euros from last year's 134 million euros.

Earnings per share were 0.05 euro, down from 2.47 euros a year ago.

Adjusted net income was 75 million euros, compared to 146 million euros a year ago. Adjusted EBIT was 105 million euros, down from 199 million euros a year ago. Adjusted EBIT margin fell to 10.3 percent from prior year's 16.3 percent.

Revenue for the quarter fell to 1.02 billion euros from 1.23 billion euros in the previous year.

The order backlog at MTU was 18.6 billion euros at year-end, compared with 19.8 billion euros in the previous year.

Further, the company's Board would recommend to propose a resolution to the Annual General Meeting to pay a dividend of 1.25 euros per share. Due to the coronavirus pandemic, the dividend paid for 2019 was the statutory minimum of 0.04 euro.

Looking ahead for fiscal 2021, MTU expects revenue to be between 4.2 billion euros and 4.6 billion euros. The adjusted EBIT margin should be between 9.5 and 10.5 percent. Adjusted net income is expected to develop in line with adjusted EBIT.

In fiscal 2020, revenues were 3.98 billion euros, and adjusted EBIT margin was 10.5 percent.

The company said the commercial maintenance business is expected to recover most clearly from the effects of the coronavirus crisis, with revenue growth of around 15 to 25 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT